Content area
Abstract
IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that 2005 total global pharmaceutical sales(a) (see endnote) grew 7 percent at constant exchange rates, to USD 602 billion. In the ten major markets, audited growth was 5.7 percent in 2005, compared with 7.2 percent the previous year. This group accounts for 81 percent of the total global pharmaceutical market, but emerging markets including China, Korea, Mexico, Russia and Turkey, all experienced double-digit growth, outpacing global performance and signaling important shifts in the marketplace.
In 2005, more than 2,300 products were in clinical development, up 9 percent from 2004 levels, and up 31 percent over the past three years. A promising range of drugs are now in Phase III clinical trials or pre-approval stage, including 96 oncology products, 51 products for treating cardiovascular disease, 37 for viral infections and HIV, and 28 for arthritis/pain. Of the total pipeline, 27 percent of these products are biologic in nature--an all-time high. Biologics also experienced strong growth overall, adding USD 7.6 billion in sales to the global pharmaceutical market in 2005. Led by Amgen, Roche/Genentech and Johnson and Johnson, this sector grew 17.1 percent in 2005, generating sales of USD 52.7 billion.
In 2005, North America, which accounts for 47 percent of global pharmaceutical sales, grew 5.2 percent, to USD 265.7 billion, while Europe experienced somewhat higher growth of 7.1 percent, to USD 169.5 billion. Sales in Latin America grew an exceptional 18.5 percent to USD 24 billion, while Asia Pacific (outside of Japan) and Africa grew 11 percent to USD 46.4 billion. Japan, the world's second largest market, which has historically posted slower growth rates, performed strongly in 2005, growing 6.8 percent to USD 60.3 billion, its highest year-over-year growth since 1991. That performance was fueled by growth in angiotensin IIs, antihistamines and oncology therapies, as well as significant uptake in geriatric-related therapies such as Aricept(R), for treating Alzheimer's, and Cabaser(R), Permax(R) and Bi Sifrol(R), for treating Parkinson's Disease.